312 related articles for article (PubMed ID: 28595433)
41. Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan.
Yoshida I; Tamura K; Miyamoto T; Shimokawa M; Takamatsu Y; Nanya Y; Matsumura I; Gotoh M; Igarashi T; Takahashi T; Aiba K; Kumagai K; Ishizawa K; Kurita N; Usui N; Hatake K
In Vivo; 2019; 33(4):1355-1362. PubMed ID: 31280230
[TBL] [Abstract][Full Text] [Related]
42. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
[TBL] [Abstract][Full Text] [Related]
43. Survey ranking of emetogenic control in children receiving chemotherapy.
Small BE; Holdsworth MT; Raisch DW; Winter SS
J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
[TBL] [Abstract][Full Text] [Related]
44. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience.
Al-Salloum HF; Al-Harbi HE; Abdelazeem A
J Oncol Pharm Pract; 2023 Sep; 29(6):1317-1325. PubMed ID: 36518002
[TBL] [Abstract][Full Text] [Related]
46. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
[TBL] [Abstract][Full Text] [Related]
47. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
[TBL] [Abstract][Full Text] [Related]
49. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
[TBL] [Abstract][Full Text] [Related]
51. Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.
Jordan K; Warr DG; Hinke A; Sun L; Hesketh PJ
Support Care Cancer; 2016 May; 24(5):1941-1954. PubMed ID: 26476625
[TBL] [Abstract][Full Text] [Related]
52. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
53. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk.
Suzuki A; Kobayashi R; Fujii H; Iihara H; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2016 Dec; 36(12):6527-6533. PubMed ID: 27919978
[TBL] [Abstract][Full Text] [Related]
54. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.
Bossi P; Cortinovis D; Fatigoni S; Cossu Rocca M; Fabi A; Seminara P; Ripamonti C; Alfieri S; Granata R; Bergamini C; Agustoni F; Bidoli P; Nolè F; Pessi MA; Macchi F; Michellini L; Montanaro F; Roila F
Ann Oncol; 2017 Oct; 28(10):2547-2551. PubMed ID: 28666335
[TBL] [Abstract][Full Text] [Related]
55. Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy.
Rogers MP; Blackburn L
Clin J Oncol Nurs; 2010 Aug; 14(4):500-4. PubMed ID: 20682506
[TBL] [Abstract][Full Text] [Related]
56. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal.
Araújo A; Tavares N; Faria AL; Gomes R; Mendonça JC; Parente B; Capela A; Barata F; Macedo A
Curr Oncol; 2023 Jan; 30(2):1529-1537. PubMed ID: 36826078
[TBL] [Abstract][Full Text] [Related]
58. Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database.
Okuyama A; Boku N; Higashi T
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1482. PubMed ID: 34176233
[TBL] [Abstract][Full Text] [Related]
59. Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea.
Lee R; Ku M; Je NK
Support Care Cancer; 2024 Feb; 32(3):190. PubMed ID: 38400861
[TBL] [Abstract][Full Text] [Related]
60. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
